

|                              |  |                           |                           |
|------------------------------|--|---------------------------|---------------------------|
|                              |  | <b>EMLc</b>               | Codes ATC: <b>L01DA01</b> |
| Indication                   | Malignant neoplasms of kidney, except renal pelvis   | Code ICD11: <b>2D40.Z</b> |                           |
| INN                          | Dactinomycin   |                           |                           |
| Type de médicament           | Chemical agent   |                           |                           |
| Type de liste                | Liste complémentaire (EML) (EMLc)  |                           |                           |
| Formulations                 | Parenteral > General injections > IV: 500 µg in vial powder for injection  |                           |                           |
| Historique des statuts LME   | Ajouté pour la première fois en 1984 (TRS 722)<br>Modifié en 2011 (TRS 965)<br>Modifié en 2015 (TRS 994)   |                           |                           |
| Sexe                         | Tous   |                           |                           |
| Âge                          | Aussi recommandé pour les enfants  |                           |                           |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique  |                           |                           |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a>  |                           |                           |
| Balises                      | <span>Cancer</span>  |                           |                           |
| Wikipédia                    | <a href="#">Dactinomycin</a>    |                           |                           |
| DrugBank                     | <a href="#">Dactinomycin</a>    |                           |                           |

## Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for Wilms tumour was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Wilms tumour is attached.

Rapport du comité d'experts 
